Physician profile
David R Jensen
NPI 1093731325
$6,672.66
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $623 · 2021: $1,121 · 2022: $1,271 · 2023: $1,548 · 2024: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,841.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,231.89 | 2019-2024 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $760.70 | 2021-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $618.36 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $585.27 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $491.59 | 2019-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $402.67 | 2019-2024 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.86 | 2019-2024 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $266.77 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $261.57 | 2019-2023 | |
| Pfizer INC. | $219.33 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $184.76 | 2022-2024 | Rexulti |
| Lundbeck LLC | $181.54 | 2022-2024 | Rexulti |
| Abbvie INC. | $167.28 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $140.61 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $90.68 | 2022-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.